ECSP067100A - Preparación enantioselectiva del derivado de quinolina - Google Patents
Preparación enantioselectiva del derivado de quinolinaInfo
- Publication number
- ECSP067100A ECSP067100A EC2006007100A ECSP067100A ECSP067100A EC SP067100 A ECSP067100 A EC SP067100A EC 2006007100 A EC2006007100 A EC 2006007100A EC SP067100 A ECSP067100 A EC SP067100A EC SP067100 A ECSP067100 A EC SP067100A
- Authority
- EC
- Ecuador
- Prior art keywords
- quinoline derivative
- quinolin
- oxy
- substituted
- enantioselective preparation
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- UWCWUCKPEYNDNV-LBPRGKRZSA-N 2,6-dimethyl-n-[[(2s)-pyrrolidin-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C)=C1NC[C@H]1NCCC1 UWCWUCKPEYNDNV-LBPRGKRZSA-N 0.000 abstract 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un proceso para la preparación de oxi-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-onas 8-sustituidas, o solvatos aceptables de las mismas. El proceso involucra hacer reaccionar una oxi-(1H)-quinolin-2-ona 5-(a-haloacetil)-8-sustituida con un agente reductor en la presencia de un agente quiral y una base, para formar una 8-(oxi-sustituida)-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-ona, el agente quiral una Fórmula I ó II:donde M, L, X, R1, R2, y R3 tienen los significados indicados en la especificación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413960.6A GB0413960D0 (en) | 2004-06-22 | 2004-06-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP067100A true ECSP067100A (es) | 2007-01-26 |
Family
ID=32799952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006007100A ECSP067100A (es) | 2004-06-22 | 2006-12-20 | Preparación enantioselectiva del derivado de quinolina |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20090054653A1 (es) |
| EP (1) | EP1791820B1 (es) |
| JP (1) | JP5064214B2 (es) |
| KR (1) | KR101179302B1 (es) |
| CN (1) | CN1968927B (es) |
| AR (2) | AR049553A1 (es) |
| AT (1) | ATE450512T1 (es) |
| AU (1) | AU2005254698B2 (es) |
| BR (1) | BRPI0512298A (es) |
| CA (1) | CA2566388C (es) |
| CY (1) | CY1109884T1 (es) |
| DE (1) | DE602005018076D1 (es) |
| DK (1) | DK1791820T3 (es) |
| EC (1) | ECSP067100A (es) |
| ES (1) | ES2337273T3 (es) |
| GB (1) | GB0413960D0 (es) |
| HR (1) | HRP20100087T1 (es) |
| IL (1) | IL179600A (es) |
| MA (1) | MA28687B1 (es) |
| MX (1) | MXPA06014695A (es) |
| MY (1) | MY142051A (es) |
| NO (1) | NO339079B1 (es) |
| NZ (1) | NZ551276A (es) |
| PE (1) | PE20060304A1 (es) |
| PL (1) | PL1791820T3 (es) |
| PT (1) | PT1791820E (es) |
| RU (1) | RU2383534C2 (es) |
| SI (1) | SI1791820T1 (es) |
| TN (1) | TNSN06408A1 (es) |
| TW (1) | TWI347317B (es) |
| WO (1) | WO2005123684A2 (es) |
| ZA (1) | ZA200609257B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0713951B8 (pt) | 2006-06-30 | 2021-05-25 | Novartis Ag | derivados de quinazolina, e composição farmacêutica |
| EP1914227A1 (en) * | 2006-08-31 | 2008-04-23 | Novartis AG | Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist |
| WO2011056929A1 (en) | 2009-11-04 | 2011-05-12 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| WO2011109276A1 (en) | 2010-03-01 | 2011-09-09 | Massachussets Institute Of Technology | Epoxidation catalysts |
| MA34373B1 (fr) | 2010-07-14 | 2013-07-03 | Novartis Ag | Composés hétérocycliques agonistes du récepteur ip |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| JP6058698B2 (ja) | 2012-01-13 | 2017-01-11 | ノバルティス アーゲー | Ｉｐ受容体アゴニストの塩 |
| ES2565826T3 (es) | 2012-01-13 | 2016-04-07 | Novartis Ag | Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados |
| US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| WO2013105065A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
| WO2013105061A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| CN104379566B (zh) * | 2012-07-11 | 2016-08-24 | 上海威智医药科技有限公司 | 茚达特罗中间体及茚达特罗的合成方法 |
| EP3848354B1 (en) | 2012-09-21 | 2022-07-27 | Crystal Pharma, S.A.U. | Process for the preparation of indacaterol and intermediates thereof |
| WO2014044288A1 (en) | 2012-09-21 | 2014-03-27 | Crystal Pharma Sa | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof |
| ES2715682T3 (es) | 2012-12-19 | 2019-06-05 | Novartis Ag | Inhibidores de la autotaxina |
| US9604981B2 (en) | 2013-02-13 | 2017-03-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| CA2898700C (en) | 2013-03-14 | 2022-07-19 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| CZ306252B6 (cs) | 2013-03-15 | 2016-10-26 | Zentiva, K.S. | Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu) |
| EP2978745B1 (en) | 2013-03-27 | 2017-03-15 | Laboratorios Lesvi, S.L. | Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one |
| EP3022201A1 (en) | 2013-07-18 | 2016-05-25 | Novartis AG | Autotaxin inhibitors |
| MX368059B (es) | 2013-07-18 | 2019-09-18 | Novartis Ag | Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica. |
| EP3092217B1 (en) | 2014-01-09 | 2020-06-03 | Davuluri, Ramamohan Rao | A novel process for preparation of indacaterol or its pharmaceutically acceptable salts |
| EP3122331A1 (en) | 2014-03-27 | 2017-02-01 | Novartis AG | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| CN105693603B (zh) * | 2014-11-24 | 2019-11-29 | 上海医药工业研究院 | 改良的马来酸茚达特罗制备工艺 |
| KR101769204B1 (ko) * | 2015-08-04 | 2017-08-17 | 씨제이헬스케어 주식회사 | 크로마놀 유도체의 신규한 제조방법 |
| ES2747905T3 (es) | 2015-09-29 | 2020-03-12 | Inke Sa | Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona |
| JP6621442B2 (ja) * | 2016-05-17 | 2019-12-18 | 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 金属イオンバッテリー |
| CN107868045A (zh) * | 2016-09-28 | 2018-04-03 | 四川海思科制药有限公司 | 一种茚达特罗中间体的制备方法 |
| CN114591236A (zh) * | 2020-12-02 | 2022-06-07 | 四川海思科制药有限公司 | 一种茚达特罗的改进制备方法 |
| CN113731406B (zh) * | 2021-10-12 | 2023-07-28 | 南京工业大学 | 一种提高钯碳活性加氢脱除保护基的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| TR199802385T2 (xx) * | 1996-05-20 | 1999-04-21 | Darwin Discovery Limited | TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler. |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| TWI324150B (en) * | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| PE20100399A1 (es) * | 2003-04-02 | 2010-06-01 | Novartis Ag | Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas |
-
2004
- 2004-06-22 GB GBGB0413960.6A patent/GB0413960D0/en not_active Ceased
-
2005
- 2005-06-17 AR ARP050102511A patent/AR049553A1/es not_active Application Discontinuation
- 2005-06-20 MY MYPI20052795A patent/MY142051A/en unknown
- 2005-06-20 PE PE2005000704A patent/PE20060304A1/es active IP Right Grant
- 2005-06-21 ES ES05770221T patent/ES2337273T3/es not_active Expired - Lifetime
- 2005-06-21 CN CN2005800195899A patent/CN1968927B/zh not_active Expired - Lifetime
- 2005-06-21 DE DE602005018076T patent/DE602005018076D1/de not_active Expired - Lifetime
- 2005-06-21 JP JP2007517180A patent/JP5064214B2/ja not_active Expired - Lifetime
- 2005-06-21 MX MXPA06014695A patent/MXPA06014695A/es active IP Right Grant
- 2005-06-21 AT AT05770221T patent/ATE450512T1/de active
- 2005-06-21 PL PL05770221T patent/PL1791820T3/pl unknown
- 2005-06-21 EP EP05770221A patent/EP1791820B1/en not_active Expired - Lifetime
- 2005-06-21 PT PT05770221T patent/PT1791820E/pt unknown
- 2005-06-21 AU AU2005254698A patent/AU2005254698B2/en not_active Expired
- 2005-06-21 CA CA2566388A patent/CA2566388C/en not_active Expired - Lifetime
- 2005-06-21 HR HR20100087T patent/HRP20100087T1/hr unknown
- 2005-06-21 BR BRPI0512298-8A patent/BRPI0512298A/pt not_active Application Discontinuation
- 2005-06-21 RU RU2007102228/04A patent/RU2383534C2/ru active
- 2005-06-21 TW TW094120524A patent/TWI347317B/zh active
- 2005-06-21 KR KR1020067026958A patent/KR101179302B1/ko not_active Expired - Lifetime
- 2005-06-21 WO PCT/EP2005/006686 patent/WO2005123684A2/en not_active Ceased
- 2005-06-21 DK DK05770221.9T patent/DK1791820T3/da active
- 2005-06-21 SI SI200530921T patent/SI1791820T1/sl unknown
- 2005-06-21 US US11/569,140 patent/US20090054653A1/en not_active Abandoned
- 2005-06-21 NZ NZ551276A patent/NZ551276A/en not_active IP Right Cessation
-
2006
- 2006-11-07 ZA ZA200609257A patent/ZA200609257B/en unknown
- 2006-11-27 IL IL179600A patent/IL179600A/en active IP Right Grant
- 2006-12-08 TN TNP2006000408A patent/TNSN06408A1/en unknown
- 2006-12-20 EC EC2006007100A patent/ECSP067100A/es unknown
- 2006-12-28 MA MA29571A patent/MA28687B1/fr unknown
-
2007
- 2007-01-22 NO NO20070400A patent/NO339079B1/no unknown
-
2010
- 2010-03-01 CY CY20101100199T patent/CY1109884T1/el unknown
-
2011
- 2011-09-14 AR ARP110103340A patent/AR082981A2/es unknown
-
2012
- 2012-05-01 US US13/461,204 patent/US20120220775A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP067100A (es) | Preparación enantioselectiva del derivado de quinolina | |
| IS2520B (is) | Nikótínamíð afleiður nytsamlegar sem P38 hindrar | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| CO6270257A2 (es) | Derivados de piridazinona | |
| PE20091623A1 (es) | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA | |
| ECSP10010361A (es) | Derivados de piridazinona | |
| ECSP088598A (es) | Derivados de piridazinona | |
| UY38952A (es) | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y composiciones farmacéu-ticas que las contienen | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| TW200608977A (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| MX2009006864A (es) | Inhibidores novedosos de c jun-n-terminal cinasas. | |
| CR9881A (es) | Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos | |
| MXPA05012894A (es) | Benzofuranos 3-sustituidos como agentes terapeuticos. | |
| EA200870103A1 (ru) | Феноксиуксусные кислоты в качестве активаторов ppar дельта | |
| PE20060818A1 (es) | Compuestos de triazoloquinoleina que aumentan la produccion de apolipoproteina a-1 | |
| NO20071574L (no) | Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander. | |
| ATE346067T1 (de) | Carbolinderivate | |
| NO20073839L (no) | Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette | |
| ATE368666T1 (de) | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren | |
| TW200616976A (en) | Pyrimidine derivatives | |
| MXPA05012953A (es) | Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos. | |
| PE20070795A1 (es) | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa | |
| ATE419323T1 (de) | Schmiermittelzusammensetzung | |
| TW200628153A (en) | Novel compounds | |
| DE60127131D1 (de) | Tricyclische imidazopyridine |